Elanco US Inc.

The present disclosure provides processes for making enantiomerically pure isoxazoline compounds of formula (1), The present disclosure also provides processes for making enantiomerically pure isoxazoline compounds of formula (1) characterized by improving the enantiomeric purity of 3-methyl-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]thiophene-2-carboxylic acid by crystallization.

Disclosed herein are porcine interferon alpha variants (pINF-α) comprising a synthetic amino acid at select locations in pINF-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pINF-α variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.

Palatable oral dosage formulations are provided including an effective amount of an isoxazoline parasiticidal agent, an avermectin, and a pyrazinoisoquinoline, and optionally one or more additional active ingredients, such as a tetrahydropyrimidine.

Provided are various embodiments relating to variant IgG Fc polypeptides with altered FcRn binding activity. Also provided are polypeptides and pharmaceutical compositions comprising the variant IgG Fc polypeptides described herein. Polypeptides comprising variant IgG Fc polypeptides of the present invention may have extended half-life in vivo. Such products may be used in methods to treat disease in companion animals, such as canines, felines, and equines.

Modified bovine G-CSF polypeptides and uses thereof are provided.

Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.

Disclosed a method of improving growth performance in feedlot cattle by administering an effective amount of lubabegron or a pharmaceutically acceptable salt thereof, at a dose of between about 3.5 and 22 mg*kg −1 dry matter. In one aspect, the lubabegron is administered over a period of 56 days for up to 16 to 2 days prior to harvest.

Palatable oral dosage formulations are provided including an effective amount of an isoxazoline parasiticidal agent, an avermectin, and a pyrazinoisoquinoline, and optionally one or more additional active ingredients, such as a tetrahydropyrimidine.

The present disclosure relates to compositions comprising capsicum, functional mineral compounds, and yeast cell wall. Furthermore, methods of feeding the composition to animals such as bovines are provided to demonstrate beneficial effects on the animals. The compositions and methods described herein can benefit overall animal wellbeing and future productivity, especially in younger animals.